newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective

  • The U.S. Securities and Exchange Commission declared the Form S-4 Registration Statement effective on October 30, 2026, for the proposed merger between Chemomab Therapeutics and Scipher Medicine.
  • Chemomab shareholders of record as of October 29, 2026, will vote on the merger at a special meeting scheduled for December 4, 2026, at 3:00 p.m. Israel Time.
  • If approved, the combined company is expected to close in early 2027, operate under the name "Scipher Medicine Corporation," \& trade on Nasdaq under the ticker symbol "SCIP."
  • Pre-merger Chemomab equity holders are expected to own approximately 32% of the combined company, while pre-merger Scipher equity holders are expected to own approximately 68%.
  • Chemomab shareholders will receive contingent value rights (CVRs) tied to milestones for the drug nebokitug.
  • The combined entity will integrate Scipher's SPECTRA™ AI platform with Chemomab's nebokitug, which is planned for a Phase 2 trial in rheumatoid arthritis starting in the first half of 2027.
  • A private placement financing is expected to occur immediately prior to the merger closing.
  • Shareholders representing approximately 20% of Chemomab's voting power have signed voting support agreements to approve the transaction.
  • The merger received unanimous approval from the boards of directors of both companies.